G. Herma Renkema

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This has led to the search for more peripherally restricted CB1R(More)
  • 1